Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,780.40
(
-0.07%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.36
(
-2.08%
)
Bitcoin
70,451.20
(
-1.11%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197714

Friday, 12/04/2015 10:07:47 AM

Friday, December 04, 2015 10:07:47 AM

Post# of 257262
AMGN submits EU MAA for Humira FoB:

http://finance.yahoo.com/news/amgens-first-biosimilar-marketing-authorization-070000371.html

AMGN submitted a 351(k) BLA to the FDA for this product candidate on 11/25/15 (#msg-118766059).

ABBV’s ancillary patent protection for Humira is not as strong in the EU as it is in the US, so even ABBV expects FoB competition for Humira in the EU after the European CoM matter patent on Humira expires in 2018.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now